The Manufacturers Life Insurance Company Has $266.40 Million Position in Merck & Co., Inc. $MRK

Key Points

• The Manufacturers Life Insurance Company increased its Merck stake by 12.3% in the second quarter, acquiring 227,589 additional shares and bringing its position to 2.07 million shares valued at approximately $266.4 million. Institutional investors and hedge funds collectively own 76.07% of Merck.
• Analysts maintain a generally positive outlook, with 17 Buy ratings and eight Hold ratings producing a consensus “Moderate Buy” rating and an average price target of $151.32. Several firms recently raised their targets, although Jefferies and RBC downgraded the stock to Hold and Sector Perform, respectively.
• Merck reported quarterly revenue of $16.61 billion, above expectations, while earnings exceeded estimates; the company also declared a quarterly dividend of $0.85 per share, equivalent to a 2.3% annualized yield. Executives sold approximately $30 million of stock during the latest quarter.

The Manufacturers Life Insurance Company boosted its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 12.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,073,176 shares of the company's stock after purchasing an additional 227,589 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.08% of Merck & Co., Inc. worth $266,403,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MRK. Round Rock Advisors LLC boosted its holdings in Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company's stock valued at $1,272,000 after purchasing an additional 66 shares during the period. Cascade Financial Partners LLC raised its position in shares of Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company's stock valued at $1,895,000 after buying an additional 80 shares in the last quarter. Somerset Trust Co raised its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after buying an additional 81 shares in the last quarter. Stonebridge Financial Group LLC boosted its stake in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after buying an additional 81 shares during the period. Finally, Stronghold Wealth Management L.L.C. lifted its position in shares of Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after acquiring an additional 82 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRK. The Goldman Sachs Group lifted their price objective on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a research note on Friday, August 21st. Jefferies Financial Group downgraded Merck & Co., Inc. from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Daiwa Securities Group upgraded Merck & Co., Inc. from a "neutral" rating to an "outperform" rating and set a $143.00 price target on the stock in a research note on Wednesday, August 12th. Royal Bank Of Canada downgraded Merck & Co., Inc. from an "outperform" rating to a "sector perform" rating and upped their price objective for the stock from $142.00 to $150.00 in a research report on Thursday, August 20th. Finally, Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Seventeen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $151.32.

Merck & Co., Inc. Stock Down 1.9%

Shares of MRK opened at $144.68 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The stock has a market capitalization of $356.96 billion, a price-to-earnings ratio of 115.75, a PEG ratio of 6.42 and a beta of 0.21. The stock has a fifty day moving average of $136.22 and a 200-day moving average of $124.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter in the prior year, the firm earned $2.13 EPS. The business's revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Richard Deluca sold 11,699 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares of the company's stock, valued at $14,501,282.21. The trade was a 9.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Zachary sold 80,315 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Insiders own 0.17% of the company's stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts raised price targets: HSBC lifted its target from $150 to $172 and maintained a “buy” rating, while Guggenheim raised its target to $170. Leerink Partners also increased its target from $127 to $161 and assigned an “outperform” rating. These revisions indicate continued confidence in Merck’s earnings potential and pipeline. Guggenheim Increases Merck Price Target
• Positive Sentiment: Pipeline strategy may help address Keytruda risks: Merck is pairing antibody-drug conjugates with Keytruda in women’s cancer treatments, an effort to expand its oncology franchise and offset the eventual impact of Keytruda’s patent cliff. Merck Pairs ADCs With Keytruda
• Neutral Sentiment: Investors are reassessing Merck’s valuation: A comparison with Eli Lilly highlights that Merck is trading at a higher valuation despite its slower expected growth, prompting questions about whether its pipeline, cash generation and defensive characteristics justify the premium. Merck Stock Versus Eli Lilly
• Neutral Sentiment: Market attention remains elevated: Merck was among the stocks most watched by Zacks users, suggesting strong investor interest but not necessarily a change in fundamentals. Merck Investor Attention
• Negative Sentiment: Shares declined with the broader market and underperformed during the session: The trading update provided no new company-specific catalyst, leaving valuation concerns and the Keytruda patent-cliff debate as the primary pressures on the stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.